

ASX Announcement

Results of meeting

30 November 2020 – Race Oncology Limited (**Race** or the **Company**) (ASX: RAC) advises that its Annual General Meeting of Shareholders was held today at 9.00 am (AEDT).

In accordance with Listing Rule 3.13.2 and section 251AA(2) of the Corporations Act 2001 (Cth), the Company advises that the details of the resolutions and the proxies received in respect of each resolution are set out in the attached proxy summary.

-ENDS-

About Race Oncology (ASX: RAC)

Race Oncology is an ASX listed precision oncology company with a Phase II/III cancer drug called Bisantrene.

Bisantrene is a potent inhibitor of the Fat mass and obesity associated (FTO) protein. Over-expression of FTO has been shown to be the genetic driver of a diverse range of cancers. Race is exploring the use of Bisantrene as a new therapy for melanoma and clear cell renal cell carcinoma, which are both frequent FTO over-expressing cancers. The Company also has compelling clinical data for the use of Bisantrene as a chemotherapeutic agent with reduced cardiotoxicity in Acute Myeloid Leukaemia (AML), breast and ovarian cancers and is investigating its use in these areas.

Race is pursuing outsized commercial returns for shareholders via its 'Three Pillar' strategy for the clinical development of Bisantrene. See more at www.raceoncology.com.

Release authorised by:

Phil Lynch, CEO/MD on behalf
of the Race Board of Directors
phillip.lynch@raceoncology.com

Media contact:

Jane Lowe
+61 411 117 774
jane.lowe@irdepartment.com.au

Disclosure of Proxy Votes

Race Oncology Limited

Annual General Meeting

Monday, 30 November 2020



Automic

GPO Box 5193, Sydney, NSW 2001

P 1300 288 664 (aus) or +61 (0)2 9698 5414 (world)

F +61 (0)2 8583 3040 E hello@automic.com.au

ABN 27 152 260 814

In accordance with section 251AA of the Corporations Act 2001, the following information is provided in relation to resolutions put to members at the meeting.

			Proxy Votes				Poll Results (if applicable)		
Resolution	Decided by Show of Hands (S) or Poll (P)	Total Number of Proxy Votes exercisable by proxies validly appointed	FOR	AGAINST	ABSTAIN	PROXY'S DISCRETION	FOR	AGAINST	ABSTAIN
01 Adoption of Remuneration Report	P	14,686,571	14,563,694 99.16%	53,475 0.36%	26,055	69,402 0.47%	30,751,007 99.83%	53,475 0.17%	26,055
02 Election of Director – Professor Borje Andersson	P	18,884,143	18,814,741 99.63%	0 0.00%	35,510	69,402 0.37%	35,002,054 100.00%	0 0.00%	9,235,510
03 Election of Director – Phillip Lynch	P	18,467,194	18,397,792 99.62%	0 0.00%	452,459	69,402 0.38%	43,785,105 100.00%	0 0.00%	452,459
04 Re-election of Director – Dr John Cullity	P	15,098,465	15,029,063 99.54%	0 0.00%	3,821,188	69,402 0.46%	40,416,376 100.00%	0 0.00%	3,821,188
05 Adoption of Incentive Performance Rights Plan	P	14,515,641	14,252,679 98.19%	163,475 1.13%	121,985	99,487 0.69%	30,470,077 99.47%	163,475 0.53%	121,985
06 Issue of Incentive Performance Rights to Director – Professor Borje Andersson	P	14,628,816	14,048,854 96.04%	480,475 3.28%	8,810	99,487 0.68%	30,266,252 98.44%	480,475 1.56%	8,810
07 Issue of Incentive Options to Director – Phillip Lynch	P	14,628,816	14,037,854 95.96%	491,475 3.36%	427,959	99,487 0.68%	30,255,252 98.40%	491,475 1.60%	427,959



			Proxy Votes				Poll Results (if applicable)		
Resolution	Decided by Show of Hands (S) or Poll (P)	Total Number of Proxy Votes exercisable by proxies validly appointed	FOR	AGAINST	ABSTAIN	PROXY'S DISCRETION	FOR	AGAINST	ABSTAIN
08 Issue of Incentive Options to Director – Professor Borje Andersson	P	14,628,816	14,037,854 95.96%	491,475 3.36%	8,810	99,487 0.68%	30,255,252 98.40%	491,475 1.60%	8,810
09 Issue of Incentive Options to Director – Dr Daniel Tillett	P	14,628,816	14,037,854 95.96%	491,475 3.36%	8,810	99,487 0.68%	30,255,252 98.40%	491,475 1.60%	8,810
10 Replacement of Constitution	P	18,771,668	18,631,441 99.25%	40,740 0.22%	147,985	99,487 0.53%	43,948,839 99.91%	40,740 0.09%	247,985
11 Approval of 7.1a Mandate	P	18,771,668	18,566,381 98.91%	105,800 0.56%	147,985	99,487 0.53%	43,883,779 99.76%	105,800 0.24%	247,985
12 Ratification of prior issue of Shares – Listing Rule 7.1	P	10,197,168	10,069,206 98.75%	28,475 0.28%	147,485	99,487 0.98%	35,486,604 99.92%	28,475 0.08%	147,485

